Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor

• Published in: Clinical pharmacokinetics Vol. 54; no. 7; pp. 761 - 770
• Main Authors: Hirano, Masaru, Meyers, Dan, Golla, GangaRaju, Pal, Parasar, Pinot, Pascale, Lin, TsuHan, Majumdar, Tapan, Rebello, Sam, Sunkara, Gangadhar, Chen, Jin
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.07.2015; Springer Nature B.V
• Subjects: Acetates - administration & dosage; Acetates - blood; Acetates - pharmacokinetics; Aminopyridines - administration & dosage; Aminopyridines - blood; Aminopyridines - pharmacokinetics; Body Mass Index; Diacylglycerol O-Acyltransferase - antagonists & inhibitors; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - blood; Enzyme Inhibitors - pharmacokinetics; Female; Glucuronides - blood; Hepatic Insufficiency - blood; Hepatic Insufficiency - metabolism; Humans; Hyperlipoproteinemia Type I - blood; Hyperlipoproteinemia Type I - drug therapy; Hyperlipoproteinemia Type I - metabolism; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Protein Binding; Moderate Hepatic Impairment; Severe Hepatic Impairment; Hepatic Impairment; Diacylglycerol Acyltransferase; Plasma Protein Binding

Background and Objective Pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, is under development to treat familial chylomicronemia syndrome. The potential impact of hepatic impairment on the pharmacokinetics of pradigastat was evaluated in this study. Methods In this study, a single or...